Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
A legfontosabb adatok
- Ki végzi
- Tongji Hospital
- Hol
- Wuhan (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 6 fő, tervezett
- Kezdés
- 2026. ápr. 1.
- Várható befejezés
- 2028. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Universal CD19 CAR-γδT Cell Injection
- Cyclophosphamide
- Fludarabine
- A regiszteradat frissítve
- 2026. május 12.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan 18–75 éves felnőtteket keres, akiknek ellenanyag okozta autoimmun ideg- vagy izombetegsége visszatért, vagy a korábbi kezelésekre nem javult. A QH103 sejtinjekció biztonságát vizsgálják.
- Életkor
- 18–75 év
- Nem
- Mindkét nem részt vehet.
- A betegség stádiuma
- Az alábbi betegségek egyike: sclerosis multiplex, NMOSD, autoimmun agyvelőgyulladás, CIDP, myasthenia gravis, MOGAD vagy idiopátiás gyulladásos izombetegség. Mindegyikre külön fogyatékossági vagy aktivitási feltétel vonatkozik, például sclerosis multiplexben EDSS 2–7, myasthenia gravisban MG-ADL pontszám 6 vagy több.
- Korábbi kezelés
- A betegséget a szokásos kezelések (például szteroid, immunszuppresszáns, immunglobulin vagy plazmacsere) nem tudták jól kontrollálni, vagy a beteg nem tűrte őket. Korábbi CAR-T sejtterápia nem megengedett.
- Biomarker vagy leletérték
- A betegségre jellemző ellenanyag-pozitivitás: AQP4 NMOSD-ben, MOG MOGAD-ban, legalább egy autoantitest autoimmun agyvelőgyulladásban, CIDP-ben, myasthenia gravisban és idiopátiás gyulladásos izombetegségben.
A részvétel fő kizáró okai
- Nem kontrollált vagy kezelést igénylő fertőzés
- Pozitív hepatitis B, hepatitis C, HIV vagy szifilisz teszt
- Aktív vagy nem gyógyult daganat az elmúlt 5 évben
- Nem megfelelő csontvelő-, máj-, vese-, szív- vagy véralvadási működés
- Részvétel másik klinikai vizsgálatban az elmúlt 3 hónapban
A regiszter feltételei, szó szerint
Mind a 40 feltétel megnézéseKevesebb
Ki nem vehet részt
- Participation in any other clinical trial within 3 months prior to enrollment
- Prior treatment with CAR-T cell therapy
- Myasthenia gravis crisis not effectively controlled within 2 weeks prior to enrollment
- History of cerebrovascular accident, including transient ischemic attack or stroke, within 6 months prior to enrollment
- History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulation therapy
- History of severe drug allergy or allergic diathesis
- Presence of or suspected uncontrolled or treatment-requiring fungal, bacterial, viral, or other infections
- History of active/unresolved malignant tumors within the past 5 years
- Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer above the detection limit; positive for hepatitis C virus (HCV) antibody with detectable peripheral blood HCV RNA; positive for human immunodeficiency virus (HIV) antibody; or positive for Treponema pallidumserology
- History of definite psychiatric disorders or history of substance abuse involving psychotropic drugs that cannot be discontinued
- History of severe adverse reactions to cyclophosphamide or fludarabine
- History of other autoimmune diseases (e.g.,Crohn's disease, systemic lupus erythematosus) that, within the past 2 years, have resulted in end-organ damage or required systemic immunosuppressive therapy (excluding the disease populations specified for enrollment in the study protocol)
- Any medical condition that may interfere with the assessment of the safety or efficacy of the study treatment
- Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study
- Organ function that does not meet the following requirements (except for abnormalities caused by the autoimmune disease itself):; Bone Marrow Function: White blood cell count ≥1×10⁹/L; absolute neutrophil count ≥1×10⁹/L (no treatment with colony-stimulating factors within 2 weeks prior to the test); hemoglobin ≥60 g/L; Liver Function: ALT ≤3×ULN (except if elevated due to inflammatory myopathy); AST ≤3×ULN (except if elevated due to inflammatory myopathy); Indirect bilirubin (IBIL) ≤1.5×ULN (except for Gilbert's syndrome); Total bilirubin ≤3.0×ULN; Renal Function: Creatinine clearance (CrCl) ≥30 mL/min (eGFR ≥30 mL/min/1.73m²) (calculated by Cockcroft-Gault formula, except for acute decreases in CrCl due to the disease itself); Coagulation Function: International normalized ratio (INR) ≤1.5×ULN; Prothrombin time (PT) ≤1.5×ULN; Cardiac Function: Left ventricular ejection fraction (LVEF) ≥55% and no clinically significant cardiac disease
- Subjects with a history indicative of congenital immunoglobulin deficiency
- Male or female participants unwilling to practice contraception from the time of informed consent until 6 months after treatment completion
Egyéb feltételek
- Common Inclusion Criteria:
- Aged 18-75 years (inclusive), any gender
- Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or practice abstinence during the study treatment period and for at least 6 months after the end of the study treatment. Female subjects of childbearing potential must have a negative serum HCG test within 7 days before study enrollment and must not be breastfeeding
- The subject's expected survival, as judged by the investigator, is ≥12 weeks
- Voluntarily participate in this trial and sign the informed consent form; Disease-Specific Inclusion Criteria:; 1、Multiple Sclerosis (MS): Clinically confirmed as progressive MS (including Primary Progressive PPMS or Secondary Progressive SPMS) or Relapsing-Remitting MS (RMS) according to the revised 2017 McDonald criteria. Disability status at screening must meet an EDSS score of 2-7 (inclusive) .For participants with RMS, despite standardized use of DMTs, they must have documented evidence meeting one of the following conditions prior to signing the informed consent:
- Two relapses were recorded within the first 2 years of screening
- One recurrence was recorded within the first year prior to screening
- Select the results of Gd-enhanced MRI scans that were positive within the previous year (if there is no record of a positive Gd-enhanced scan in the previous year, the results of the screening MRI scan can be used); 2、Neuromyelitis Optica Spectrum Disorder (NMOSD): Participants with AQP4 antibody-positive NMOSD meeting the 2015 IPND NMOSD diagnostic criteria, and meeting one of the following:
- Treatment with at least one immunosuppressant for over 1 year, or intolerance to immunosuppressant treatment, with suboptimal symptom control
- At least 2 documented relapses within the last 12 months, or 3 documented relapses within the last 24 months with at least 1 relapse occurring within the 12 months prior to screening; 3、Autoimmune Encephalitis (AE): Participants with a clinical diagnosis of Autoimmune Encephalitis based on the 2016 International Diagnostic Criteria, meeting all of the following requirements:
- Positive for at least one relevant autoantibody
- Inadequate symptom control with or intolerance to previous standardized treatment with glucocorticoids and at least one immunosuppressant/immunomodulator (including CD20 monoclonal antibody)
- An episode of autoimmune encephalitis within 3 months prior to signing the informed consent form
- Disability status at screening meeting a modified Rankin Scale (mRS) score ≥ 2 or a CASE score ≥ 4 ; 4、Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Participants diagnosed with antibody-positive CIDP according to the 2021 EAN/PNS diagnostic criteria, with an INCAT Disability Scale total score between 2 and 9, and meeting one of the following:
- Inadequate symptom control despite standardized use of at least one first-line therapy (corticosteroids, intravenous immunoglobulin, or plasma exchange) for over 3 months
- Intolerance to corticosteroids, intravenous immunoglobulin, and plasma exchange due to side effects or other reasons; 5、Myasthenia Gravis (MG): Participants diagnosed with antibody-positive MGFA Class II-IV Myasthenia Gravis according to the 2020 MGFA diagnostic criteria, with a Myasthenia Gravis Activities of Daily Living (MG-ADL) profile (Appendix 6) total score ≥ 6, and meeting one of the following:
- Standardized treatment with at least one immunosuppressant for over 1 year, with one of the following indicating inadequate control: (1) persistent weakness affecting daily life, (2) worsening MG symptoms and/or crisis episodes despite standard treatment, or (3) intolerance to immunosuppressant therapy
- Requiring maintenance therapy with plasma exchange or intravenous immunoglobulin; 6、Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody----- - Associated Disease (MOGAD): Participants with a clinical diagnosis of MOGAD based on the 2023 International MOGAD Diagnostic Criteria, meeting all of the following:
- Positive for MOG autoantibody via cell-based assay (CBA)
- Disability status at screening meeting a modified Rankin Scale (mRS) score ≥ 2
- Inadequate symptom control with or intolerance to previous standardized treatment with glucocorticoids and at least one immunosuppressant / immunomodulator (including CD20 monoclonal antibody); 7、Idiopathic Inflammatory Myopathies (IIM): Patients clinically diagnosed with refractory, antibody-positive Idiopathic Inflammatory Myopathy (IIM) based on the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ACR) classification criteria. At screening, at least one muscle enzyme (CK, AST, ALT, ALD, LDH) must be ≥1.5 times the upper limit of normal (ULN); OR the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) for dermatomyositis must be ≥6 (Appendix 7); OR there must be evidence of active myositis within the last 6 months from at least one of the following: MRI, electromyography, or muscle biopsy. The patient must test positive for at least one myositis-specific antibody (MSA), myositis-associated antibody (MAA), or antinuclear antibody (ANA). Additionally, they must meet one of the following criteria:
- Treatment with corticosteroids for at least 1 month, combined with standardized use of at least one immunosuppressant/immunomodulator (e.g., azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus, cyclophosphamide, leflunomide, intravenous immunoglobulin, etc.) for over 3 months, resulting in inadequate symptom control
- Intolerance to the aforementioned conventional treatment regimens due to side effects or other reasons
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Helyszínek itt: Kína
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, KínaContact: Daishi TianRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of recurrent/refractory antibody-mediated neurological autoimmune diseases.
A vizsgálat csoportja
- Patients with Relapsed/Refractory Antibody-Mediated Neurological Autoimmune DiseasesA vizsgált kezelés
Kezelés: Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide és Fludarabine
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Open-Label Clinical Study to Evaluate the Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- Illeszkedési kérdések
- Forrás: NCT07526493: ki vehet részt
- A regiszteradat frissítve
- 2026. május 12.